Abstract:Background The type and quantities of antidepressants are increasing, but the efficacy and safety of first-line and emerging drugs vary between studies. In this article, we estimated the efficacy and safety of first-line and emerging antidepressants (anti-inflammatory drugs and ketamine). Method ystematic search of EMBASE, ERIC, MEDLINE, psycARTICLES, and psycINFO without language restriction for studies on the depression, depressive symptoms, antidepressants, fluoxetine (Prozac), paroxetine, escitalopram, sertraline, fluvoxamine, venlafaxine, duloxetine, NSAIDs, anti-cytokine drugs or pioglitazone published before May 1st, 2019. Information on study characteristics, depression or depressive symptoms, antidepressants and the descriptive statistics (including efficacy and safety of antidepressants) was extracted independently by 2 investigators. Estimates were pooled using random-effects meta-analysis. Differences by study-level characteristics were estimated using stratified meta-analysis and meta-regression. The response and remission of antidepressants were used as clinical evaluation indicators, and the evaluation criteria were clinical depression scales. OR value of antidepressants as assessed by meta-analysis. Results The literature search retrieved 5529 potentially relevant articles of which 49 studies were finally included. We compared the efficacy of antidepressants (seven first-line antidepressants (fluoxetine, paroxetine, escitalopram, sertraline, fluvoxamine, venlafaxine, duloxetine), there kinds of anti-inflammatory drugs(NASIDs, cytokine-inhibitor, pioglitazone) and ketamine) by comparing the OR values. Conclusion The three drugs with the highest OR value in response were NASID (OR = 3.62(1.58, 8.32)), venlafaxin (OR = 3.50(1.83, 6.70)) and ketamine (OR = 3.28(1.89, 5.68)), while the highest OR value in remission were NASID (OR = 3.17(1.60, 6.29)), ketamine (OR = 2.99(1.58, 5.67)) and venlafaxin (OR = 2.55(1.72, 3.78)). Through reading the literature, we found 69 SNPs associated with depression. Major depression was a debilitating disorder that could ultimately lead to enormous societal and economical challenge [ [1] Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006; 110: 135-370 Crossref PubMed Scopus (459) Google Scholar ]. The number of person which affected by depression was up to 16% of the population worldwide. More than 300 million individuals were estimated to suffer depression these days [ 1 Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006; 110: 135-370 Crossref PubMed Scopus (459) Google Scholar , 2 Abdallah C.G. Adams T.G. Kelmendi B. Esterlis I. Sanacora G. Krystal J.H. Ketamine's Mechanism of Action: A Path to Rapid-Acting Antidepressants. Depress. Anxiety. 2016; 33: 689-697 Crossref PubMed Scopus (121) Google Scholar ]. Therefore, it is apparent that safety and effective treatments for depression are necessary. In the 1930 s, the first drug for schizophrenia was discovered. This finding was a landmark for the emerging of biological psychiatry. In the 1950 s, pharmacologists had stumbled upon the antidepressant effect of imipramine. Since then, every 30 years, the use of antidepressants had made a pulsatile leap. Selective serotonin reuptake inhibitors (SSRIs) are the most widely-prescribed psychiatric drugs for the treatment of depression. However, the efficacy was variable and incomplete: 60%–70% of the patients do not experience remission, while 30%–40% do not show a significant response [ 3 Lehmann H.E. Ban T.A. The history of the psychopharmacology of schizophrenia. Canadian J Psych Revue Canadienne de Psych. 1997; 42: 152-162 Crossref PubMed Scopus (87) Google Scholar , 4 Stroup D.F. Berlin J.A. Morton S.C. Olkin I. Williamson G.D. Rennie D. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-2012 Crossref PubMed Scopus (15343) Google Scholar ]. Nevertheless, SSRIs, SNRIs (selective serotonin-norepinephrine reuptake inhibitors, which can block norepinephrine at the same time) and NaSSAs (norepinephrine and selective serotonin receptor agonist), constituted the first-line clinical drugs. Nearly 30 years after the outbreak of SSRIs, antidepressants have ushered in a new chapter. It has been found that anti-inflammatory drugs could also have the small and moderate antidepressant effect and it’s widely discussed [ [5] Kappelmann N. Lewis G. Dantzer R. Jones P.B. Khandaker G.M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018; 23: 335-343 Crossref PubMed Scopus (331) Google Scholar ]. More than 40 anti-inflammatory drugs have been certificated to have antidepressant effects in preclinical and clinical studies [ [6] Adzic M. Brkic Z. Mitic M. Francija E. Jovicic M.J. Radulovic J. et al. Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr Neuropharmacol. 2018; 16: 176-209 Crossref PubMed Scopus (79) Google Scholar ]. The antidepressant that has been approved for use recently is ketamine. There is no comprehensive comparison of the efficacy of all these drugs. In this review, we tried to estimate the efficacy and safety of first-line antidepressants, anti-inflammatory drugs and ketamine. On the other hand, with the development of GWAS, SNPs related to depression have been reported, and the corresponding mechanisms have been elaborated, respectively. However, patients with these SNPs have not been treated with individualized drugs according to the mechanisms. We hope to push this process forward through the summary of this article. Methods Search Strategy and Study Eligibility.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors

Clinical Application of Therapeutic Drug Monitoring and Pharmacogenetics in Psychiatry, with a Focus on Belgium

Clinical pharmacological innovation in the treatment of depression

Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial

Pharmacogenetic‐Guided Treatment of Depression: Real‐World Clinical Applications, Challenges, and Perspectives

Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology

Application of Antidepressants in Depression: A Systematic Review and Meta-Analysis

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis

Pharmacogenomic Clinical Support Tools for the Treatment of Depression

Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials

Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials

Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study

The Application of Pharmacogenetic Testing in Psychiatry for Treatment-Resistant Disorders: Optimal Timing and Implementation, a literature review

Effectiveness of Antidepressants in Combination with Psychotherapy

AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.